Unique ID issued by UMIN | UMIN000019018 |
---|---|
Receipt number | R000021947 |
Scientific Title | The evaluations of glucose metabolism, bone metabolism, vascular endothelial function and lipid metabolism by the hormone which regulates circadian rhythm in type 2 diabetes. |
Date of disclosure of the study information | 2015/09/14 |
Last modified on | 2015/09/15 18:05:52 |
The evaluations of glucose metabolism, bone metabolism, vascular endothelial function and lipid metabolism by the hormone which regulates circadian rhythm in type 2 diabetes.
The evaluations of glucose metabolism, bone metabolism, vascular endothelial function and lipid metabolism by the hormone which regulates circadian rhythm in type 2 diabetes.
The evaluations of glucose metabolism, bone metabolism, vascular endothelial function and lipid metabolism by the hormone which regulates circadian rhythm in type 2 diabetes.
The evaluations of glucose metabolism, bone metabolism, vascular endothelial function and lipid metabolism by the hormone which regulates circadian rhythm in type 2 diabetes.
Japan |
type 2 diabetes and non diabetes patients
Endocrinology and Metabolism |
Others
NO
To determine the effect of glucose metabolism, bone metabolism, vascular endothelial function and lipid metabolism by the hormone which regulates circadian rhythm in type 2 diabetes
Bio-availability
Correlation between melatonin and glucose metabolism in type 2 diabetes and non-diabetic patients
Observational
20 | years-old | <= |
80 | years-old | > |
Male and Female
(1)Subjects with FPG <180 mg/dl
(2)Subjects who have not been administered insulin or insulin resistance improving drug four weeks before admission.
(3)Subjects who have never recieved treatment of osteoporosis
(4)Subjects who give consent document about participation in the clinical study
(1) With diabetic ketoacidosis, diabetic coma and type 1 diabetes
(2) With an abnormality in the endocrine hormone levels
(3)With severe infections
(4)Subjects who have administered melatonin or melatonin receptor agonist
(5)Subjects with cognitive decline (less than 23 points in the MMSE).
(6)Subjects With malignancy within 5 years
(7) Considered as inadequate by the investigator
168
1st name | |
Middle name | |
Last name | Yosuke Okada |
University of Occupational and Environmental Health
First Department of Internal Medicine, School of Medicine
1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu
093-603-1611
y-okada@med.uoeh-u.ac.jp
1st name | |
Middle name | |
Last name | kenichi tanaka |
University of Occupational and Environmental Health
First Department of Internal Medicine, School of Medicine
1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu
093-603-1611
kenichi.tanaka0801@gmail.com
University of Occupational and Environmental Health, Japan, First Department of Internal Medicine, School of Medicine
University of Occupational and Environmental Health, Japan, First Department of Internal Medicine, School of Medicine
Other
NO
2015 | Year | 09 | Month | 14 | Day |
Unpublished
Enrolling by invitation
2014 | Year | 12 | Month | 09 | Day |
2014 | Year | 12 | Month | 09 | Day |
cross-sectional study
Recruitment of Subject:
from December/2014 to May 2017, patients who meet the inclusion/exclusion criteria
Parameters:6-sulfatoxymelatonin, glucose metabolism, bone metabolism, vascular endothelial function, lipid metabolism, Pittsburgh sleep questionnaire
2015 | Year | 09 | Month | 14 | Day |
2015 | Year | 09 | Month | 15 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000021947